Phuturdex › Diseases › Respiratory Insufficiency
Drugs in development · updated 30 October 2026
Respiratory Insufficiency: drugs in development
As of 30 October 2026 there are 12 active clinical trials (recruiting or ongoing, phases I–III) on 25 drugs for respiratory Insufficiency. 8 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| NoradrenalineNoradrenalin | III | 1 | NCT05014581 |
| Phosphocreatine | III | 1 | NCT06503016 |
| AgenT-797 | II | 1 | NCT07615010 |
| AtibuclimabIC14 | II | 1 | NCT04488081 |
| Aviptadil | II | 1 | NCT04488081 |
| Cenicriviroc | II | 1 | NCT04488081 |
| ENA-001 | II | 1 | NCT06137638 |
| Rhu-pGSN | II | 1 | NCT05947955 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MorphineArymo Er®, Morphabond Er® | II–III | 2 | NCT04011163 |
| Albuterol SulfateSalbutamol, Proair Respiclick® | III | 1 | NCT05527704 |
| DoxapramDopram® | III | 1 | NCT04430790 |
| HydromorphoneExalgo®, Palladone® | II–III | 1 | NCT06785571 |
| NalbuphineNubain® | II–III | 1 | NCT06785571 |
| DexamethasoneDexametasone, Dextenza | II | 2 | NCT07334379 |
| ApremilastOtezla, Apremilast Accord® | II | 1 | NCT04488081 |
| CelecoxibCelebrex Capsule, Elyxyb® | II | 1 | NCT04488081 |
| CyclosporineCyclosporine A, Cyclosporin Capsules | II | 1 | NCT04488081 |
| CyproheptadinePeriactin® | II | 1 | NCT04488081 |
| Dornase alfaPulmozyme | II | 1 | NCT04488081 |
| FamotidineFluxid®, Pepcid Ac® | II | 1 | NCT04488081 |
| IcatibantFirazyr®, Icatibant Accord® | II | 1 | NCT04488081 |
| ImatinibSTI571, Imkeldi® | II | 1 | NCT04488081 |
| NarsoplimabYartemlea® | II | 1 | NCT04488081 |
Sorted by most advanced phase and number of active trials. Showing 15 of 17 drugs.
All 25 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Nasal Obstruction 8 drugs
- Influenza 68 drugs
- Common cold 4 drugs
- Asthma 84 drugs
- Respiratory sound 4 drugs
- Dyspnea 7 drugs
- Lung disease 104 drugs
- Respiratory disease 57 drugs
- Cough 14 drugs
- Pharyngitis 5 drugs
- Fever 4 drugs
Broader categories
- Respiratory disease 57 drugs
- Respiration disorder 6 drugs
- Lung disease 104 drugs
- Infection 71 drugs
- Respiratory tract infection 46 drugs
- Neurologic Manifestations 15 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D012131 “Respiratory Insufficiency”.